NICE TA Adherence Check List
|
|
- Percival Dorsey
- 5 years ago
- Views:
Transcription
1 NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs or procedures are evaluated. Following this evaluation the drug or procedure is approved or not approved for use in the NHS Patient Access Scheme - discount scheme agreed between the manufacturer of the drug and the Department of Health which enables patient access to high cost drugs If clinically appropriate NICE has recommended the drug can be use for the indication stated. NICE has reviewed the drug and has recommended the drug CANNOT be used for the indication stated No evidence was received by NICE from the manufacturer of the drug so NICE were unable to proceed with the appraisal Reason to prescribe the specified drug Colour Key Implemented with 90 days of TA release Not implemented within the 90 days of TA release NICE TA Indication Drug Approval Release Date Available on Local Formulary TA274 Diabetic macular oedema Ranibizumab 27/02/13 TA275 Stroke & Systemic embolism Apixaban 27/02/13 TA267 Heart Failure II - IV Ivabradine 28/11/12 TA260 Chronic migraine Botulinum toxin A 27/11/12 TA265 Bone Metastases for solid tumours Denosumab 24/10/12 TA264 Acute ischaemic stoke Alteplase 26/09/12 TA261 deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban 25/07/12 TA256 Stroke prevention in AF Rivaroxaban 23/05/12 TA249 Stroke prevention in AF Dabigatran etexilate 15/03/12 TA247 Rheumatoid arthritis Tocilizumab with PAS 22/02/12 TA248 Type 2 diabetes Exenatide LAR 22/02/12 TA244 COPD Roflumilast 25/01/12 TA245 Prevention of VT after total Hip or Knee replacement in Adults Apixaban 25/01/12 TA236 ACS Ticagrelor 26/10/11 TA233 Ankylosing spondylitis Golimumab with PAS 24/08/11 TA229 Macular oedema associated with retinal vein occlusion Dexamethasone implant (Ozurdex) 27/07/11 TA232 Partial onset seizures Retigabine 27/07/11 TA225 Rheumatoid arthritis (2nd line ) Golimumab with PAS 22/06/11 TA223 Intermiittent claudication associated with peripheral vasular disease Naftidrofuryl oxalate 25/05/11 TA220 Psoriatic arthritis Golimumab with PAS 27/04/11 Donepezil 23/03/11 Galantamine 23/03/11 TA217 Alzheimer's disease Memantine 23/03/11 Rivastigmine 23/03/11 Rivastigmine (patch) 23/03/11 Alendronate 26/01/11 TA160 Osteoporosis Primary prevention Etidronate 26/01/11 Risedronate 26/01/11 Strontium ranelate 26/01/11 Teriparatide 26/01/11 Alendronate 26/01/11 TA161 Osteoporosis Secondary Prevention Etidronate 26/01/11 Risedronate 26/01/11 Strontium ranelate 26/01/11 Raloxifene 26/01/11 TA213 Schizophrenia (15-17yo) Aripiprazole (oral) 26/01/11 TA210 Occlusive vascular events Clopidogrel 15/12/10 Dipyridamole (MR) 15/12/10 TA211 Refractory constipation in women Prucalopride 15/12/10 TA203 Type 2 diabetes Liraglutide 27/10/10 TA204 Post-menopausal osteoporosis Denosumab 27/10/10 Abatacept 25/08/10 Notes
2 Adalimumab 25/08/10 TA195 RA (after failure of TNF) Etanercept 25/08/10 Infliximab 25/08/10 Rituximab 25/08/10 TA197 AF Dronedarone 25/08/10 Adalimumab 25/08/10 TA199 Psoriatic arthritis Etanercept 25/08/10 Infliximab 25/08/10 TA188 Growth failure in children Somatropin 26/05/10 TA187 Crohn's disease Adalimumab 19/05/10 Infliximab 19/05/10 TA186 Rheumatoid arthritis Certolizumab pegol with PAS 24/02/10 TA182 ACS Prasugrel 28/10/09 TA180 Psoriasis Ustekinumab with PAS 23/09/09 TA177 Chronic hand eczema Alitretinoin 26/08/09 TA170 VTE prophylaxis (post hip or knee replacement) Rivaroxaban 22/04/09 TA168 Treatment of influenza Oseltamivir 25/02/09 Zanamivir 25/02/09 TA164 Hyperuricaemia Febuxostat 17/12/08 TA163 UC (acute exacerbations) Infliximab 17/12/08 This guidance relates to the use of infliximab within it marketing authorisation. Therefore in children between the ages of 6 to 17 who meet the clinical criteria their treatment would funded via Commissioning Board TA157 VTE prophylaxis (post hip or knee replacement) Dabigatran etexilate 24/09/08 TA158 Prevention of influenza Oseltamivir 24/09/08 Zanamivir 24/09/08 TA155 AMD Ranibizumab 27/08/08 TA146 Psoriasis Adalimumab 25/06/08 TA142 TA143 Ca treatment-induced anaemia Ankylosing spondylitis Darbopoetin Adalimumab Epoetin alfa, beta & delta Etanercept TA134 Psoriasis Infliximab 23/01/08 TA132 Hypercholesterolaemia Ezetimibe 28/11/07 Adalimumab 24/10/07 TA130 RA (first TNF) Etanercept 24/10/07 Infliximab 24/10/07 TA123 Smoking Cessation Varenicline 25/07/07 Anastrozole 22/11/06 TA112 Breast Ca Exemestane 22/11/06 Letrozole 22/11/06 TA103 Psoriasis Etanercept 26/07/06 TA82 Eczema Pimecrolimus 01/08/04 Tacrolimus 01/08/04 TA77 Insomnia Zaleplon 01/04/04 TA68 PDT of AMD Verteprofin 01/09/03 TA64 Growth hormone deficiency in adults Somatropin 01/08/03 TA53 Type 1&2 diabetes Insulin glargine 01/12/02 Alteplase 01/10/02 TA52 Acute MI Reteplase 01/10/02 Streptokinase 01/10/02 Tenecteplase 01/10/02 TA20 MND Riluzole 01/01/01 TA268 Metastatic melanoma Ipilimumab 12/12/12 TA269 Locally Adv. Or metastatic BRAF V600 mutation-positive unresectable metastatic Verumafenib 12/12/12 TA266 Cystic Fibrosis Mannitol 28/11/12 TA258 NSCLC with EGFR activating mutations Erlotinib with PAS 27/06/12 TA259 Metastatic Castration resistant Prostate Ca Abiraterone (Zytiga) 27/06/12 TA252 Genotype 1 chronic Hepatitis C Telaprevir 25/04/12 TA253 Genotype 1 chronic Hepatitis C Bocepravir 25/04/12 TA254 highly active relapsing remitting multiple sclerosis (In Adults) Fingolimod with PAS 25/04/12
3 TA246 Hypersensitivity to bee & wasp venom Pharmalgen 22/02/12 TA243 1st line Treatment of Follicular Lymphoma stages III - IV Rituximab 25/01/12 Cyclophosphamide 25/01/12 TA241 CML dasatinib, nilotinib, imatinib (intolerant, resistant) Nilotinib 13/01/12 TA238 Juvenile Idiopathic systemic arthritis Tocilizumab with PAS 14/12/11 TA235 Osteosarcoma Mifamurtide 26/10/11 TA228 Mulitple myeloma (1st line) Thalidomide 27/07/11 Bortezomib 27/07/11 TA230 STEMI undergoing primary PCI Bivalirudin 27/07/11 TA226 Follicular NHL (maintenance) Rituximab 22/06/11 TA221 Idiopathic thrombocytopenia purpura Romiplostim with PAS 27/04/11 TA218 Myelodysplastic syndrome Azacitidine with PAS 23/03/11 TA215 Metastatic renal cell Ca (1st line) Pazopanib with PAS 23/02/11 TA216 CLL (1st line) Bendamustine 23/02/11 TA86 & TA209 Unresectable/metastatic GIST Imatinib 24/11/10 TA191 Advanced gastric Ca Capecitabine 28/07/10 TA192 Locally-advanced or metastatic NSCLC (1st line) Gefitinib with PAS 28/07/10 TA193 CLL (relapsed or refractory) Rituximab in combination with fludarabine & cyclophosphamide 28/07/10 TA190 NSCLC (maintenance) Pemetrexed 23/06/10 TA185 Advanced soft tissue sarcoma Trabectedin with PAS 24/02/10 TA184 Relapsed SCLC Topotecan (oral) 25/11/09 TA183 Cervical Ca Cisplatin (in combination) 28/10/09 Topotecan 28/10/09 TA179 GIST Sunitinib with PAS 23/09/09 TA181 NSCLC (1st line) Pemetrexed 23/09/09 TA176 Colorectal Ca (first line) Fluorouracil with PAS 26/08/09 TA176 Metastatic colorectal Ca (1st line) Cetuximab with PAS 26/08/09 TA173 Hepatitis B Tenofovir disoproxil 22/07/09 Cyclophosphamide 22/07/09 TA174 CLL Fludarabine phosphate 22/07/09 Rituximab 22/07/09 TA171 Mulitple myeloma Lenalidomide with PAS 18/06/09 TA169 Renal cell Ca (1st line) Sunitinib 25/03/09 TA162 NSCLC - treatment Erlotinib with PAS 26/11/08 TA153 Hepatitis B Entecavir 27/08/08 TA151 Type 1 diabetes CSII (adults & Children over 12 years & over) 23/07/08 TA145 Head & neck Ca (locally advanced) Cetuximab 25/06/08 TA137 Follicular non-hodgkin's lymphoma Rituximab 27/02/08 TA135 Mesothelioma Pemetrexed 23/01/08 TA133 Asthma - over 12yo & adults Omalizumab 28/11/07 TA129 Relapsed Multiple myeloma Bortezomib with PAS 24/10/07 TA127 Multiple sclerosis Natalizumab 22/08/07 TA121 Glioma Carmustine (implant) 27/06/07 Temozolomide 27/06/07 TA116 Metastatic breast Ca Gemcitabine 24/01/07 Paclitaxel 24/01/07 TA117 Secondary hyperparathyroidism Cinacalcet 24/01/07 Doxorubicin hydrochloride 21/09/06 TA109 Early Breast Ca Cyclophosphamide 21/09/06 Docetaxel 21/09/06 TA106 Hepatitis C (mild) Peginterferon alfa 26/08/06 Ribavirin 26/08/06 TA107 Early breast Ca Trastuzumab 23/08/06 TA101 Prostate Ca Docetaxel 28/06/06 Capecitabine 26/04/06 TA100 Colon Ca Fluorouracil 26/04/06 Oxaliplatin 26/04/06 TA99 Renal transplantation (adults) Basiliximab 26/04/06 TA96 Hepatitis B Adefovir dipivoxil 22/02/06 Peginterferon alfa 22/02/06 Doxorubicin hydrochloride (peg.lipsomal) 01/05/05 Topotecan 01/05/05
4 TA91 Ovarian Ca (advanced) Carboplatin 01/05/05 Cisplatin 01/05/05 Paclitaxel 01/05/05 TA85 Renal transplantation (adolescents & children) Basiliximab 22/09/04 Interferon alfa 01/01/04 TA75 Hepatitis C (moderate-severe) Peginterferon alfa 01/01/04 Ribavirin 01/01/04 TA70 CML Imatinib 01/10/03 Cyclophosphamide 01/09/03 TA65 Non-Hodgkin's lymphoma Rituximab 01/09/03 Doxorubicin hydrochloride 01/09/03 TA61 Metastatic colorectal Ca Capecitabine 01/05/03 Tegafur with uracil 01/05/03 TA55 Ovarian Ca Paclitaxel 01/01/03 TA35 Juvenile arthritis Etanercept 01/03/02 TA25 Pancreatic Ca Gemcitabine 01/05/01 TA23 Brain cancer Temozolomide 01/04/01 Buprenorphine 01/01/07 TA114 Managing Opiod Dependancy Methadone 01/01/07 Naltrexone 01/01/07 NICE Indication Drug Approval Release Date Available on Local Formulary TA271 Diabetic macular oedema Fluocinolone implant Not approved 23/01/13 No TA272 TCCU Vinflunine Not approved 23/01/13 No TA273 Benign Prostatic Hyperplasia Tadalafil Terminated 23/01/13 No TA270 AML Decitabine Not approved 12/12/12 No TA263 Adv/Metastatic breast Ca 1st line Bevacizumab Not approved 22/08/12 No TA257 HER2 +ve metastatic breast Ca Lapatinib Not approved 27/06/12 No Trastuzumab Not approved 27/06/12 No TA262 Moderate-severe UC (2nd line) Adalimumab Not approved 27/06/12 No TA255 Metastatic prostate Ca Cabazitaxel Not approved 11/05/12 No TA251 CML 1st line Dasatinib Not approved 25/04/12 No TA250 Locally advanced or metastatic breast cancer Eribulin Not approved 03/04/12 No TA242 Cetuximab Not approved 25/01/12 No Metastatic colorectal Ca (2nd line) Bevacizumab Not approved 25/01/12 No TA240 Colorectal Cancer (Metastatic) Panitumumab Not approved 25/01/12 No TA241 CML dasatinib, nilotinib, imatinib (intolerant, resistant) Dasatinib Not approved 13/01/12 No Imatinib Not approved 13/01/12 No TA239 Breast Ca Fulvestrant Not approved 14/12/11 No TA240 Metastatic colorectal Ca (2nd line) Panitumumab Terminated 14/12/11 No TA206 Indolent NHL Bendamustine Not approved 27/10/11 No TA234 RA (first TNF) Abatacept Not approved 24/08/11 No TA231 Depression Agomelatine Not approved 27/07/11 No TA227 NSCLC - maintenance Erlotinib Not approved 29/06/11 No TA224 RA (methotrexate-naïve) Golimumab Terminated 22/06/11 No TA223 Cilostazol Not approved 25/05/11 No Intermiittent claudication associated with peripheral vasular disease Inositol nicotinate Not approved 25/05/11 No Naftidrofyryl Oxalate Not approved 26/05/11 No Pentoxifylline Not approved 25/05/11 No TA222 Relapsed ovarian Ca Trabectedin Not approved 27/04/11 No TA219 Advanced RCC (2nd line) Everolimus Not approved 19/04/11 No TA214 Metastatic breast Ca Bevacizumab Not approved 23/02/11 No TA160 Primary prevention of osteoporosis Raloxifene Not approved 26/01/11 No TA212 Metastatic colorectal Ca Bevacizumab Not approved 15/12/10 No TA208 HER2 +ve metastatic gastric Ca Trastuzumab Not approved 24/11/10 No TA201 Asthma yo Omalizumab Not approved 27/10/10 No TA206 Non-Hodgkin's lymphoma Fesoterodine Not approved 27/10/10 No TA202 CLL Ofatumumab Not approved 27/10/10 No TA205 Idiopathic thrombocytopenia purpura Eltrombopag Not approved 27/10/10 No TA207 Mantle cell lymphoma Temsirolimus Terminated 27/10/10 No TA196 GIST (adjuvant) Imatinib Not approved 25/08/10 No TA189 Hepatocellular Ca Sorafenib Not approved 26/05/10 No Notes
5 Bevacizumab Not approved 29/08/09 No TA178 Renal cell Ca Sorafenib Not approved 29/08/09 No Temsirolimus Not approved 29/08/09 No Renal cell Ca (2nd line) Sunitinib Not approved 29/08/09 No TA172 Head & neck Ca (recurrent or metastatic) Cetuximab Not approved 24/06/09 No TA168 Treatment of influenza Amantadine Not approved 25/02/09 No TA158 Prevention of influenza Amantadine Not approved 24/09/08 No TA154 Hepatitis B Telbivudine Not approved 27/08/08 No TA155 AMD Pegaptanib sodium Not approved 27/08/08 No TA148 NSCLC Bevacizumab Not approved 25/06/08 No TA149 Glioblastoma multiforme Carmustine (implant) Not approved 25/06/08 No TA143 Ankylosing spondylitis Infliximab Not approved No TA140 UC (sub-acute manifestations) Infliximab Not approved 23/04/08 No TA124 NSCLC (2nd line) Pemetrexed Not approved 22/08/07 No TA119 CLL Fludarabine phosphate Not approved 28/02/07 No Bevacizumab Not approved 24/01/07 No TA118 metastatic colorectal Ca Fluorouracil Not approved 24/01/07 No Cetuximab Not approved 24/01/07 No TA108 Early breast Ca Paclitaxel Not approved 27/09/06 No TA84 Sepsis Drotrecogin alfa Withdrawn 22/09/04 No
NICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More information2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee
NICE Technology Appraisals - Time to Implementation Report - 18 December 2014 Produced by Tracy Steadman, Croydon Public Health Intelligence Team (C-PHIT), Croydon Council Date of Guidance Title of Guidance
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationRoyal Free London NHS Foundation Trust NICE Technology Appraisals and Drug Formulary Indications to date
Mar-00 TA1 Wisdom teeth removal impacted wisdom teeth should not be operated on Apr-00 TA2 Primary total hip replacement superseeded by MDA/2012/036 May-00 TA3 Ovarian cancer- taxanes Replaced by TA 55
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More informationCancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationDate of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation
NICE Technology Appraisals - Time to Implementation Report - 3 rd August 2015 Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council Date of Guidance Title of Guidance Summary
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationAppraisals. What is a NICE Technology Appraisal? Logo Here
Add A view your from Presentation NICE: Technology Title Here.. Appraisals Add Helen your Knight, name 9 and May organisation 2013 Logo Here What is a NICE Technology Appraisal? A review of clinical and
More informationNICE-approved drugs available for use within the Trust
NICE-approved drugs available for use within the Trust The following drugs have been recommended by NICE as treatment options for the indications noted below. They are listed in the Trust Medicines Formulary
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationHospital Prescribing: England 2012
Hospital Prescribing: England 2012 Published 13 November 2013 We are the trusted source of authoritative data and information relating to health and care. www.hscic.gov.uk enquiries@hscic.gov.uk Author:
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationNICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
More informationTHE DUDLEY GROUP NHS FOUNDATION TRUST FOI
THE DUDLEY GROUP NHS FOUNDATION TRUST FOI 011324 Question 2 Response shown in table below Question 4 - Please provide details of the number of applications for treatments used outside of their licensed
More informationCancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship
CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous
More informationList of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013
S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationFunding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016
Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016 Drugs can only be recharged to CCGs if used in line with local or national policies as outlined
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationFREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK
Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION
More informationReport of evidence-based assessments from Scottish Health Technologies Group August 2009
Report of evidence-based assessments from Scottish Health Technologies Group August 2009 HTA Programme: Report no HSRE/SHTG/EBA Report/2009/003A Health Services Research & Effectiveness Unit CONTENTS
More informationNorth of England Cancer Drugs Approval Group (NECDAG) Cumulative Table of Decisions August 2012
Notes: This document is updated every 2 to 3 months; please check our website www.cancernorth.nhs.uk for latest version. This document does not all contain Interim Cancer Drugs Fund s, i.e. decisions made
More informationNational Cancer Drugs Fund List Ver4.4
National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
More informationIRB INDICATION Number ENROLLED
Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationManufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationAn D. Nguyen, MD Curriculum Vitae
OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationProduct Visual Guide
Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.
More informationOur Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
More informationNational Cancer Drugs Fund List Ver4.0
National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14
More informationNational Cancer Drugs Fund List Ver2.1
National Cancer Drugs Fund List Ver2.1 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationClinical Trials OPEN to ENROLLMENT
CNS 2014 Second Quarter Clinical Trials OPEN to ENROLLMENT GAB 101 (CNS THERAPEUTICS INC): Safety of 3 mg/ml Gablofen (baclofen injection) Delivered by Intrathecal Administration Using the Synchromed II
More informationManufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 31.05.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationPayment by Results 2013/2014 Drug and Device Exclusions
Payment by Results 2013/2014 Drug and Device Exclusions 1. Introduction The tariff payment system is nationally calculated averages. It is expected that against the tariff, providers will incur a deficit
More information03 May 2016 Page 1 of 5. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationOral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing
Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing ABIRATERONE Prostate CA: castrate Prostate CA: castrate resistant metastatic dz Prostate
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationCancer-Drug Associations: A Complex System
Cancer-Drug Associations: A Complex System Ertugrul Dalkic 1,2,3, Xuewei Wang 1,4, Neil Wright 1,5, Christina Chan 1,2,3,4,6,7 * 1 Center for Systems Biology, Michigan State University, East Lansing, Michigan,
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationVolume 10; Number 4 February 2016
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationCancerPACTtm. Cancer Patients Alliance for Clinical Trials. Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011
CancerPACTtm Cancer Patients Alliance for Clinical Trials Northern Los Angeles Area ~ Adult Cancer Clinical Trials Summer / Fall 2011 Solid Tumors 1. Breast... 2 2. Central Nervous System... 4 3. Gastrointestinal...
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More informationApril May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.
April May 2014 Recommended for use within NHS Scotland April May 2014 aflibercept intravitreal (Eylea ) 954/14 For adults for the treatment of visual impairment due to macular oedema secondary to central
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationMolecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Cancer Clinical Trials in the Sacramento Area Summer 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.3 3. Gastrointestinal
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationFor Health Professionals Who Care For Cancer Patients
April 2018 Volume 21, No. 4 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Palbociclib for Metastatic Breast Cancer, Adjuvant Capecitabine for Breast
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationWorld Health Organization: Essential Medicines and Devices for Cancer:
World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationPrice comparison of high-cost medicines 2015
Price comparison of high-cost medicines 2015 Brief report Commissioned by the Federal Ministry of Health and Women s Affairs Price comparison of high-cost medicines 2015 Brief report Authors: Sabine Vogler
More informationApril 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name
April 2015 May 2015 RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date Advice Published aclidinium / formoterol fumarate dehydrate (Duaklir Genuair) Almirall
More informationCENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered
More informationSummary of Main Points from the Meeting held on Monday 13 th February 2017
Summary of Main Points from the Meeting held on Monday 13 th February 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the December 2016 Medicines Group meeting were
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More information